Immunization of Children Between 8 Weeks & 2 Years of Age With GSK

Clinical Trial Description

This protocol posting has been updated according to Protocol Amendment 2, September 2010. The impacted sections are arms and inclusion criteria. ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT01641133` - Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™	Phase 3
Completed	`NCT01204658` - Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants	Phase 2
Completed	`NCT00370396` - Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.	Phase 3
Completed	`NCT02838407` - Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.	N/A
Completed	`NCT00523770` - Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoniae	N/A
Completed	`NCT00756067` - Evaluation of Pneumococcal Vaccine Formulations in Elderly	Phase 1
Completed	`NCT00345358` - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT01153893` - Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria	Phase 3
Completed	`NCT00307541` - Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT00547248` - Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines	Phase 3
Withdrawn	`NCT01160055` - Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children	N/A
Completed	`NCT00370227` - Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine	Phase 3
Completed	`NCT00390910` - Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants	Phase 3
Completed	`NCT00985751` - Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination	Phase 2
Withdrawn	`NCT01031329` - Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey	N/A
Completed	`NCT00307554` - A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study	Phase 3
Completed	`NCT02270944` - Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine	Phase 2
Completed	`NCT01235949` - Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment	Phase 4
Completed	`NCT00985465` - Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali	Phase 3
Completed	`NCT00861380` - Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease	Phase 3

NCT number	NCT01175083
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	June 1, 2011
Completion date	May 23, 2013

Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms